

1. Hall EJ, Giaccia AJ. *Radiobiology for the Radiologist*. Philadelphia: Lippincott Williams & Williams; 2012.
2. Fowler JF. Developing aspects of radiation oncology. *Med Phys* 1981;8:427–434.
3. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. *Nat Rev Mol Cell Biol* 2008;9:759–769.
4. Thompson LH. Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. *Mutat Res* 2012;751:158–246.
5. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. *Cancer Cell* 2002;2:103–112.
6. Bartek J, Lukas J, Chk1 and Chk2 kinases in checkpoint control and cancer. *Cancer Cell* 2003;3:421–429.
7. Kitagawa R, Bakkenist CJ, McKinnon PJ, et al. Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway. *Genes Dev* 2004;18:1423–1438.
8. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. *Genes Dev* 2001;15:2177–2196.
9. Mailand N, Podtelejnikov AV, Groth A, et al. Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. *EMBO J* 2002;21:5911–5920.
10. Donzelli M, Draetta GF. Regulating mammalian checkpoints through Cdc25 inactivation. *EMBO Rep* 2003;4:671–677.
11. Tsvetkov L. Polo-like kinases and Chk2 at the interface of DNA damage checkpoint pathways and mitotic regulation. *IUBMB Life* 2004;56:449–456.
12. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. *Clin Cancer Res* 2010;16:376–383.
13. Giaccia A, Weinstein R, Hu J, et al. Cell cycle-dependent repair of double-strand DNA breaks in a gamma-ray-sensitive Chinese hamster cell. *Somat Cell Mol Genet* 1985;11:485–491.
14. Kemp LM, Sedgwick SG, Jeggo PA. X-ray sensitive mutants of Chinese hamster ovary cells defective in double-strand break rejoining. *Mutat Res* 1984;132:189–196.
15. Helleday T, Lo J, van Gent DC, et al. DNA double-strand break repair: from mechanistic understanding to cancer treatment. *DNA Repair (Amst)* 2007;6:923–935.
16. Hefferin ML, Tomkinson AE. Mechanism of DNA double-strand break repair by non-homologous end joining. *DNA Repair (Amst)* 2005;4:639–648.
17. Ma Y, Pannicke U, Schwarz K, et al. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. *Cell* 2002;108:781–794.
18. Grawunder U, Wilm M, Wu X, et al. Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells. *Nature* 1997;388:492–495.
19. Chen L, Trujillo K, Sung P, et al. Interactions of the DNA ligase IV-XRCC4 complex with DNA ends and the DNA-dependent protein kinase. *J Biol Chem* 2000;275:26196–26205.
20. Tsukuda T, Fleming AB, Nickoloff JA, et al. Chromatin remodelling at a DNA double-strand break site in *Saccharomyces cerevisiae*. *Nature* 2005;438:379–383.
21. Yang YG, Saidi A, Frappart PO, et al. Conditional deletion of Nbs1 in murine cells reveals its role in branching repair pathways of DNA double-strand breaks. *EMBO J* 2006;25:5527–5538.
22. Esashi F, Galkin VE, Yu X, et al. Stabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2. *Nat Struct Mol Biol* 2007;14:468–474.
23. Sleeth KM, Sorensen CS, Issaeva N, et al. RPA mediates recombination repair during replication stress and is displaced from DNA by checkpoint signalling in human cells. *J Mol Biol* 2007;373:38–47.
24. Littlefield LG, Kleinerman RA, Sayer AM, et al. Chromosome aberrations in lymphocytes—biomonitors of radiation exposure. *Prog Clin Biol Res* 1991;372:387–397.
25. Toulany M, Rodemann HP. Membrane receptor signaling and control of DNA repair after exposure to ionizing radiation. *Nuklearmedizin* 2010;49: S26–S30.
26. Barcellos-Hoff MH, Akhurst RJ. Transforming growth factor-beta in breast cancer: too much, too late. *Breast Cancer Res* 2009;11:202.
27. Deng X, Yin X, Allan R, et al. Ceramide biogenesis is required for radiation-induced apoptosis in the germ line of *C. elegans*. *Science* 2008;322:110–115.
28. Thompson LH, Suit HD. Proliferation kinetics of x-irradiated mouse L cells studied WITH TIME-lapse photography. II. *Int J Radiat Biol Relat Stud Phys Chem Med* 1969;15:347–362.
29. Sowa Resat MB, Morgan WF. Radiation-induced genomic instability: a role for secreted soluble factors in communicating the radiation response to non-irradiated cells. *J Cell Biochem* 2004;92:1013–1019.
30. Elkind MM. The initial part of the survival curve: does it predict the outcome of fractionated radiotherapy? *Radiat Res* 1988;114:425–436.
31. McCulloch EA, Till JE. The sensitivity of cells from normal mouse bone marrow to gamma radiation in vitro and in vivo. *Radiat Res* 1962;16:822–832.
32. Withers HR. Recovery and repopulation in vivo by mouse skin epithelial cells during fractionated irradiation. *Radiat Res* 1967;32:227–239.
33. Withers HR, Elkind MM. Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation. *Int J Radiat Biol Relat Stud Phys Chem Med* 1970;17:261–267.
34. Suit H, Wette R. Radiation dose fractionation and tumor control probability. *Radiat Res* 1966;29:267–281.
35. O'Neill K, Lyons SK, Gallagher WM, et al. Bioluminescent imaging: a critical tool in pre-clinical oncology research. *J Pathol* 2010;220:317–327.
36. Hewitt HB, Wilson CW. Survival curves for tumor cells irradiated in vivo. *Ann N Y Acad Sci* 1961;95:818–827.
37. Hill RP, Bush RS. A lung-colony assay to determine the radiosensitivity of cells of a solid tumour. *Int J Radiat Biol Relat Stud Phys Chem Med* 1969;15:435–444.
38. Elkind MM, Sutton-Gilbert H, Moses WB, et al. Radiation response of mammalian cells grown in culture. V. Temperature dependence of the repair of x-ray damage in surviving cells (aerobic and hypoxic). *Radiat Res* 1965;25:359–376.
39. Elkind MM, Whitmore GF. *Radiobiology of Cultured Mammalian Cells*. New York: Gordon and Breach; 1967.
40. Mottram JC. Factors of importance in radiosensitivity of tumors. *Br J Radiol* 1936;9:606.
41. Palcic B, Skarsgard LD. Reduced oxygen enhancement ratio at low doses of ionizing radiation. *Radiat Res* 1984;100:328–339.
42. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. *Br J Cancer* 1955;9: 539–549.
43. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. *Semin Radiat Oncol* 1996;6:10–21.
44. Machtay M, Pajak TF, Suntharalingam M, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). *Int J Radiat Oncol Biol Phys* 2007;69:1008–1017.
45. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. *Lancet* 2003;362:1255–1260.
46. Janssens GO, Rademakers SE, Terhaard CH, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. *J Clin Oncol* 2012;30:1777–1783.
47. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. *Nat Med* 2004;10:145–147.
48. Lapi SE, Voller TF, Welch MJ. Positron emission tomography imaging of hypoxia. *PET Clin* 2009;4:39–47.
49. Lee NY, Mechalakos JG, Nehmeh S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. *Int J Radiat Oncol Biol Phys* 2008;70:2–13.
50. Schaub D, Xie MW, Ratikan JA, et al. Regulatory T cells in radiotherapeutic responses. *Front Oncol* 2012;2:90.
51. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. *J Natl Cancer Inst* 2013;105:256–265.
52. Lawrence TS, Davis MA, Tang HY, et al. Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S phase progression. *Int J Radiat Biol* 1996;70:273–280.
53. Lawrence TS, Chang EY, Hahn TM, et al. Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. *Int J Radiat Oncol Biol Phys* 1996;34:867–872.
54. Eisbruch A, Shewach DS, Bradford CR, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. *J Clin Oncol* 2001;19:792–799.
55. Ben-Josef E, Schipper M, Francis IR, et al. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2012;84:1166–1171.
56. Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. *Clin Cancer Res* 2001;7:2246–2253.
57. Wilson GD, Bentzen SM, Harari PM. Biologic basis for combining drugs with radiation. *Semin Radiat Oncol* 2006;16:2–9.
58. Bradley JD, Paulus R, Graham MV, et al. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group—RTOG 9705. *J Clin Oncol* 2005;23:3480–3487.
59. Nyati MK, Morgan MA, Feng FY, et al. Integration of EGFR inhibitors with radiochemotherapy. *Nat Rev Cancer* 2006;6:876–885.
60. Bonner JA, Harari PM, Giral J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. *Lancet Oncol* 2010;11:21–28.
61. Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). *J Clin Oncol* 2011;29.
62. Engelke CG, Parsels LA, Qian Y, et al. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. *Clin Cancer Res* 2013;19: 4412–4421.
63. Morgan MA, Parsels LA, Maybaum J, et al. Improving the efficacy of chemoradiation with targeted agents. *Cancer Discov* 2014;4:280–291.

64. Chalmers AJ, Lakshman M, Chan N, et al. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. *Semin Radiat Oncol* 2010;20:274–281.
65. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. *J Clin Oncol* 2000;18:3339–3345.
66. Winczura P, Jassem J. Combined treatment with cytoprotective agents and radiotherapy. *Cancer Treat Rev* 2010;36:268–275.
67. Van Dyk J, ed. Radiation oncology medical physics resources for working, teaching, and learning. In: *The Modern Technology of Radiation Oncology*. Volume 3. Medical Physics Publishing Web site. <http://www.medicalphysics.org/vandykch16.pdf>. Madison, WI: Medical Physics Publishing; 2013.
68. Karzmark C, Nunan C, Tanabe E. *Medical Electron Accelerators*. New York: McGraw-Hill Ryerson; 1993.
69. Greene D, Williams P. *Linear Accelerators for Radiation Therapy*. 2nd ed. New York: Taylor and Francis Group; 1997.
70. Fenwick JD, Tome WA, Soisson ET, et al. Tomotherapy and other innovative IMRT delivery systems. *Semin Radiat Oncol* 2006;16:199–208.
71. Curran B, Balter J, Chetty I, eds. *Integrating New Technologies into the Clinic: Monte Carlo and Image-Guided Radiation Therapy*. Madison, WI: Medical Physics Publishing; 2006.
72. Bourland J, ed. *Image-Guided Radiation Therapy*. Boca Raton, FL: Taylor & Francis; 2012.
73. Seco J, Verhaegen F, eds. *Monte Carlo Techniques in Radiation Therapy*. Boca Raton, FL: Taylor & Francis; 2013.
74. Kessler ML. Image registration and data fusion in radiation therapy. *Br J Radiol* 2006;79:S99–S108.
75. Brook K, ed. *Image Processing in Radiation Therapy*. Boca Raton, FL: Taylor & Francis Group; 2014.
76. Sovik A, Malinen E, Olsen DR. Strategies for biologic image-guided dose escalation: a review. *Int J Radiat Oncol Biol Phys* 2009;73:650–658.
77. Marks LB, Ten Haken RK, Martel MK. Guest editor's introduction to QUANTEC: a users guide. *Int J Radiat Oncol Biol Phys* 2010;76:S1–S2.
78. Li A, Alber M, Deasy JO, et al. The use and QA of biologically related models for treatment planning: short report of the TG-166 of the therapy physics committee of the AAPM. *Med Phys* 2012;39:1386–1409.
79. Bortfeld T. IMRT: a review and preview. *Phys Med Biol* 2006;51:R363–R379.
80. Webb S. *Contemporary IMRT: Developing Physics and Clinical Implementation*. London: IOP Publishing; 2005.
81. Maughan R, Yudelev M. Neutron therapy. In: Van Dyk J, ed. *The Modern Technology of Radiation Oncology*. Madison, WI: Medical Physics Publishing; 1999.
82. Hogstrom KR, Almond PR. Review of electron beam therapy physics. *Phys Med Biol* 2006;51:R455–R489.
83. Schlegel W, Bortfeld T, Grosu A, eds. *New Technologies in Radiation Oncology*. Heidelberg: Springer-Verlag; 2006.
84. Ma C-MC, Lomax T, eds. *Proton and Carbon Ion Therapy*. Boca Raton, FL: Taylor & Francis Group; 2012.
85. Venselaar J, Meigooni A, Baltas D, et al., eds. *Comprehensive Brachytherapy: Physical and Clinical Aspects*. Boca Raton, FL: Taylor & Francis Group; 2012.
86. Meredith RF. Systemic targeted radionuclide therapy symposium introduction. *Int J Radiat Oncol Biol Phys* 2006;66:S7.
87. Tripuraneni P, Watson RL, Ang KK, et al. Intersociety Radiation Oncology Summit-SCOPE II. *Int J Radiat Oncol Biol Phys* 2008;72:323–326.
88. Delaney C, Jacob S, Featherstone C, et al. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. *Cancer* 2005;104:1129–1137.
89. Zelefsky MJ, Housman DM, Pei X, et al. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2012;83:953–959.
90. Combs SE, Laperriere N, Brada M. Clinical controversies: proton radiation therapy for brain and skull base tumors. *Semin Radiat Oncol* 2013;23:120–126.
91. Overgaard J. Hypoxic radiosensitization: adored and ignored. *J Clin Oncol* 2007;25:4066–4074.
92. Mouw KW, Trofimov A, Zietman AL, et al. Clinical controversies: proton therapy for prostate cancer. *Semin Radiat Oncol* 2013;23:109–114.
93. Yu JB, Soulos PR, Herrin J, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. *J Natl Cancer Inst* 2013;105:25–32.
94. Brada M, Pijls-Johannesma M, De Ruysscher D. Proton therapy in clinical practice: current clinical evidence. *J Clin Oncol* 2007;25:965–970.
95. Douglas JG, Koh WJ, Austin-Seymour M, et al. Treatment of salivary gland neoplasms with fast neutron radiotherapy. *Arch Otolaryngol Head Neck Surg* 2003;129:944–948.
96. Shikrut M, Merrick GS, McLaughlin PW, et al. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. *Cancer* 2013;119:681–690.
97. Iyengar P, Timmerman R. Stereotactic ablative radiotherapy for non-small cell lung cancer: rationale and outcomes. *J Natl Compr Canc Netw* 2012;10:1514–1520.
98. Lo SS, Moffatt-Bruce SD, Dawson LA, et al. The role of local therapy in the management of lung and liver oligometastases. *Nat Rev Clin Oncol* 2011;8:405–416.
99. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. *J Clin Oncol* 2013;31:845–852.
100. Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. *J Clin Oncol* 2012;30:4344–4351.
101. Hellman S, Weichselbaum RR. Oligometastases. *J Clin Oncol* 1995;13:8–10.
102. Hortobagyi GN. Can we cure limited metastatic breast cancer? *J Clin Oncol* 2002;20:620–623.
103. Stameff EF, Wolchok JD, Gnjatic S, et al. The abscopal effect associated with a systemic anti-melanoma immune response. *Int J Radiat Oncol Biol Phys* 2013;85:293–295.
104. Nagtegaal ID, Gossens MJ, Marijnen CA, et al. Combinations of tumor and treatment parameters are more discriminative for prognosis than the present TNM system in rectal cancer. *J Clin Oncol* 2007;25:1647–1650.
105. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med* 2004;351:1731–1740.
106. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005;366:2087–2106.
107. Hellman S. Stopping metastases at their source. *N Engl J Med* 1997;337:996–997.
108. Marks LB, Prosnitz LR. Postoperative radiotherapy for lung cancer: the breast cancer story all over again? *Int J Radiat Oncol Biol Phys* 2000;48:625–627.
109. Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. *Lancet Oncol* 2012;13:395–402.
110. Tarnawski R, Fowler J, Skladowski K, et al. How fast is repopulation of tumor cells during the treatment gap? *Int J Radiat Oncol Biol Phys* 2002;54:229–236.
111. Peters LJ, Withers HR. Applying radiobiological principles to combined modality treatment of head and neck cancer—the time factor. *Int J Radiat Oncol Biol Phys* 1997;39:831–836.
112. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. *Lancet* 2006;368:843–854.
113. Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. *Lancet Oncol* 2012;13:145–153.
114. Adkison JB, McHaffie DR, Bentzen SM, et al. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. *Int J Radiat Oncol Biol Phys* 2012;82:184–190.
115. Feyer P, Maranzano E, Molassiotis A, et al. Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. *Support Care Cancer* 2005;13:122–128.
116. Horiot JC. Prophylaxis versus treatment: is there a better way to manage radiotherapy-induced nausea and vomiting? *Int J Radiat Oncol Biol Phys* 2004;60:1018–1025.
117. Hickok JT, Roscoe JA, Morrow GR, et al. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. *Cancer* 2005;104:1772–1778.
118. Schwartz AL, Nail LM, Chen S, et al. Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. *Cancer Invest* 2000;18:11–19.
119. Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. *Semin Radiat Oncol* 2005;15:279–283.
120. Kong FM, Hayman JA, Griffith KA, et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. *Int J Radiat Oncol Biol Phys* 2006;65:1075–1086.
121. Fleckenstein K, Gauthier-Fleckenstein B, Jackson IL, et al. Using biological markers to predict risk of radiation injury. *Semin Radiat Oncol* 2007;17:89–98.
122. Hart JP, Broadwater G, Rabbani Z, et al. Cytokine profiling for prediction of symptomatic radiation-induced lung injury. *Int J Radiat Oncol Biol Phys* 2005;63:1448–1454.
123. Barnett GC, Coles CE, Elliott RM, et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. *Lancet Oncol* 2012;13:65–77.
124. Fajardo LF. Is the pathology of radiation injury different in small vs large blood vessels? *Cardiovasc Radiat Med* 1999;1:108–110.
125. Delanian S, Porcher R, Rudant J, et al. Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. *J Clin Oncol* 2005;23:8570–8579.
126. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Adv Enzyme Regul* 1984;22:27–55.
127. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. *Int J Radiat Oncol Biol Phys* 1979;5:85–91.

128. Tannock IF. Treatment of cancer with radiation and drugs. *J Clin Oncol* 1996;14:3156–3174.
129. Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. *Radiother Oncol* 2011;100:33–40.
130. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. *J Natl Cancer Inst* 1996;88:1210–1215.
131. De Ruyscher D, Belderbos J, Reymen B, et al. State of the art radiation therapy for lung cancer 2012: a glimpse of the future. *Clin Lung Cancer* 2013;14: 89–95.
132. Klopp AH, Eifel PJ. Chemoradiotherapy for cervical cancer in 2010. *Curr Oncol Rep* 2011;13:77–85.
133. Chun PY, Feng FY, Scheurer AM, et al. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. *Cancer Res* 2006;66: 981–988.